Trials / Completed
CompletedNCT01251978
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
Phase 2 Study to Evaluate the Efficacy of High Dose Ranibizumab as Adjuvant in the Treatment of Choroidal Melanoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- New England Retina Associates · Academic / Other
- Sex
- All
- Age
- 50 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that might be needed to control the tumor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab 2 mg | intravitreal injections of ranibizumab once a month, times 3. |
| DRUG | 0.5 mg Ranibizumab | 6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months. |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2012-07-01
- Completion
- 2012-08-01
- First posted
- 2010-12-02
- Last updated
- 2016-10-19
- Results posted
- 2016-10-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01251978. Inclusion in this directory is not an endorsement.